400 reports of this reaction
1.4% of all DOLUTEGRAVIR SODIUM reports
#18 most reported adverse reaction
BONE DENSITY DECREASED is the #18 most commonly reported adverse reaction for DOLUTEGRAVIR SODIUM, manufactured by ViiV Healthcare Company. There are 400 FDA adverse event reports linking DOLUTEGRAVIR SODIUM to BONE DENSITY DECREASED. This represents approximately 1.4% of all 28,565 adverse event reports for this drug.
Patients taking DOLUTEGRAVIR SODIUM who experience bone density decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BONE DENSITY DECREASED is a less commonly reported adverse event for DOLUTEGRAVIR SODIUM, but still significant enough to appear in the safety profile.
In addition to bone density decreased, the following adverse reactions have been reported for DOLUTEGRAVIR SODIUM:
The following drugs have also been linked to bone density decreased in FDA adverse event reports:
BONE DENSITY DECREASED has been reported as an adverse event in 400 FDA reports for DOLUTEGRAVIR SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
BONE DENSITY DECREASED accounts for approximately 1.4% of all adverse event reports for DOLUTEGRAVIR SODIUM, making it a notable side effect.
If you experience bone density decreased while taking DOLUTEGRAVIR SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.